2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Shareholder Vote Results for Director Elections at TG Therapeutics
Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
Announces Positive Topline Results from Phase 3 ENHANCE Trial
Earnings Release
News
Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Q1
FY 2024
Q3
Q2
FY 2023 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Confidential Treatment Order
Correspondence
Submission Upload